Does TRICARE Cover Zepbound?

TRICARE Formulary Placement for Zepbound

Zepbound sits on the non-preferred specialty tier of the TRICARE Uniform Formulary, which the Department of Defense Pharmacy and Therapeutics Committee updates quarterly. This placement means the drug is available but carries a higher copay and stricter access controls than preferred-tier medications.

At a military treatment facility (MTF) pharmacy, TRICARE beneficiaries pay $0 for any formulary medication, including specialty drugs. The catch: most MTF pharmacies do not stock Zepbound because demand outpaces DoD procurement contracts. Beneficiaries who fill through TRICARE retail network or mail-order pharmacy (Express Scripts) face specialty-tier copays that can range from $77 to $325 per 28-day supply, depending on the specific TRICARE plan (Prime, Select, or TRICARE For Life) 1.

The Uniform Formulary listing does not guarantee automatic dispensing. Every Zepbound prescription routed outside an MTF triggers the prior-authorization gateway described in the next section. The DoD P&T Committee's December 2024 review confirmed tirzepatide's formulary retention but flagged ongoing cost-utilization monitoring, signaling that tier placement could shift if expenditures exceed projections 2.

Prior-Authorization Criteria: What TRICARE Requires

Getting PA approval is the single biggest barrier between a TRICARE beneficiary and a Zepbound prescription. The process is moderate in difficulty. Not impossible, but not rubber-stamped either.

TRICARE's managed-care contractor (currently Express Scripts for pharmacy benefits) evaluates PA requests against criteria drawn from the FDA-approved labeling and the Endocrine Society's 2024 pharmacotherapy guidelines 3. Your prescriber must document:

1. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea).
2. Failed lifestyle intervention of at least 3 to 6 months, including dietary counseling and increased physical activity.
3. Clinical rationale for tirzepatide over preferred formulary alternatives (if step therapy applies).
4. Absence of contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

PA decisions typically arrive within 5 to 10 business days. Urgent requests can be expedited to 72 hours if the prescriber documents medical necessity for accelerated review. The Endocrine Society's 2024 clinical practice guideline states, "Tirzepatide and semaglutide should be considered first-line pharmacotherapy for patients with obesity who have not achieved sufficient weight loss with lifestyle modification alone" 3. Including this guideline language in the PA request strengthens the clinical case.

Step-Therapy Requirements: Does TRICARE Make You Try Something Else First?

Some TRICARE plans enforce step therapy before approving Zepbound. This means your provider may need to show that you tried and failed (or are intolerant to) a preferred-tier weight-management agent first.

The most common step-therapy sequence requires a documented 90-day trial of one of the following before Zepbound approval:

• Semaglutide 2.4 mg (Wegovy), the GLP-1 receptor agonist on TRICARE's preferred list
• Metformin (off-label for weight management), sometimes accepted as a first step for patients with prediabetes or insulin resistance
• Phentermine-topiramate (Qsymia), though this agent carries its own PA requirements

Failure is defined as less than 5% total body weight loss after 90 days at a therapeutic dose, or documented intolerance (nausea requiring discontinuation, for example). If you already tried Wegovy through TRICARE and did not reach your weight-loss target, that history satisfies the step-therapy gate. Your prescriber should include pharmacy claims data or chart notes showing the dates, doses, and outcomes of the prior trial.

Not every TRICARE plan enforces step therapy for anti-obesity medications. Active-duty service members on TRICARE Prime may face different formulary management rules than retirees on TRICARE For Life. Confirm with your regional contractor which requirements apply to your specific benefit category 4.

The Clinical Case for Zepbound: SURMOUNT-1 Data

Understanding the efficacy data helps both prescribers and patients build a stronger PA submission. The key trial is SURMOUNT-1.

SURMOUNT-1 (N=2,539) randomized adults with obesity (BMI ≥30, or ≥27 with comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo, all with lifestyle intervention. At 72 weeks, participants on tirzepatide 15 mg achieved a mean body-weight reduction of 20.9%, compared with 3.1% for placebo 4. The 10 mg group lost 19.5% and the 5 mg group lost 15.0%. These results exceeded the weight-loss benchmarks seen with semaglutide 2.4 mg in the STEP-1 trial (N=1,961), which showed 14.9% mean weight loss at 68 weeks versus 2.4% for placebo 5.

Beyond the scale, SURMOUNT-1 demonstrated reductions in waist circumference (average 19.4 cm in the 15 mg arm), improvements in systolic blood pressure, and favorable shifts in lipid panels 4. Dr. Ania Jastreboff, lead investigator of SURMOUNT-1, noted at presentation: "These data represent a new threshold of weight reduction achievable with pharmacotherapy in people living with obesity" 4.

These numbers matter for your TRICARE PA because they demonstrate that tirzepatide is not a marginal improvement over existing options. A prescriber who cites SURMOUNT-1 in the PA narrative establishes that Zepbound offers clinically distinct efficacy, which is the standard TRICARE reviewers weigh when evaluating non-preferred-tier drugs.

How Much Does Zepbound Cost Through TRICARE?

The manufacturer list price for Zepbound is $1,059 per month (all dose strengths). What a TRICARE beneficiary actually pays depends entirely on the pharmacy channel.

MTF pharmacy (on-base): $0 copay. If your MTF stocks Zepbound and you have an approved PA, you pay nothing. The practical problem is availability. Most MTFs have limited supply of GLP-1/GIP receptor agonists due to procurement volume constraints.

TRICARE retail pharmacy: Specialty-tier copays apply. Under TRICARE Prime, the specialty copay for a 30-day supply at a retail pharmacy is typically $77. TRICARE Select beneficiaries may pay more, up to $325 for a 90-day supply through mail order, depending on whether the drug is classified as a specialty or non-formulary item in their benefit year 1.

TRICARE For Life (TFL): TFL is a Medicare wraparound. Because Medicare Part D added anti-obesity medication coverage effective January 2026 under the Treat and Reduce Obesity Act provisions, TFL beneficiaries may now access Zepbound through their Part D plan with TFL covering residual cost-sharing. This is new territory, and TFL claims processing for anti-obesity medications is still stabilizing 6.

Manufacturer savings card: Eli Lilly offers a Zepbound savings card for commercially insured patients, but TRICARE is a federal program. Federal beneficiaries are not eligible for manufacturer copay assistance cards. This restriction applies across all TRICARE plan types, including TRICARE Select, which sometimes resembles commercial insurance but remains a federal benefit.

How to Appeal a TRICARE Denial for Zepbound

If your PA is denied, do not stop there. TRICARE has a structured appeal process, and denials for anti-obesity medications are frequently overturned when the appeal includes stronger clinical documentation.

Step 1: Review the denial letter. The letter will cite the specific formulary criterion that was not met. Common reasons include insufficient documentation of BMI, missing evidence of failed lifestyle intervention, or incomplete step-therapy documentation.

Step 2: File a reconsideration with Express Scripts. Your prescriber submits additional clinical notes addressing the gap identified in the denial. Include recent lab work (fasting glucose, HbA1c, lipid panel), a detailed weight-management history, and a letter of medical necessity. The Obesity Medicine Association recommends that letters of medical necessity "include specific comorbidity burden, prior treatment failures with dates and outcomes, and a citation to the FDA-approved indication" 7.

Step 3: Escalate to the TRICARE regional contractor. If the reconsideration fails, file a formal appeal through your regional contractor (Humana Military for the East region, Health Net Federal Services for the West). This second-level review is conducted by a physician reviewer who may request a peer-to-peer call with your prescribing provider.

Step 4: Request an independent external review. Under 10 U.S.C. § 1095c, TRICARE beneficiaries have the right to an independent review by an external organization. This is the final administrative remedy before any further options would require congressional inquiry or TRICARE ombudsman involvement.

The average appeal timeline from initial denial to second-level decision is 30 to 60 days. Preparing thorough documentation at the reconsideration stage can collapse this timeline significantly.

Active-Duty vs. Retiree Coverage Differences

TRICARE is not one plan. It is a family of plans, and coverage nuances vary by beneficiary category.

Active-duty service members (TRICARE Prime) receive the most favorable access. Prescriptions filled at MTF pharmacies cost $0, and PA turnaround times tend to be faster because military providers submit directly through the Defense Health Agency network. Active-duty members also have access to obesity-medicine clinics at larger military medical centers, where multi-disciplinary teams can initiate Zepbound and manage the PA process internally.

Retirees and dependents (TRICARE Select or Prime) face the standard specialty copays described above. Retirees over age 65 transition to TRICARE For Life, which layers over Medicare. This group now benefits from Medicare Part D's expanded anti-obesity medication coverage, but coordination of benefits between TFL and Part D can create processing delays during the first year of implementation.

Reserve and Guard members (TRICARE Reserve Select) have a benefit structure similar to TRICARE Select, with the same formulary and PA requirements. The key difference is premium cost, not drug-access rules 8.

Timeline: From Prescription to First Injection

A realistic timeline for a TRICARE beneficiary starting Zepbound, from the initial prescriber visit to the first self-administered injection, looks like this:

Week 1: Provider visit. BMI documented, comorbidities assessed, lifestyle-intervention history reviewed. If step therapy applies and no prior trial exists, the provider may need to prescribe a preferred agent first and wait 90 days. If step therapy is satisfied or waived, the provider submits the PA.

Week 2 to 3: PA processing. Standard turnaround is 5 to 10 business days. Urgent requests may resolve in 72 hours.

Week 3 to 4: If approved, the prescription routes to your chosen pharmacy. Mail-order delivery through Express Scripts typically takes 5 to 7 business days. MTF availability depends on stock.

Week 4 to 5: First injection. Zepbound starts at 2.5 mg once weekly for the first 4 weeks, then escalates to 5 mg. The maintenance dose of 10 mg or 15 mg is reached over 20 to 32 weeks depending on tolerability.

If a denial and appeal are involved, add 30 to 60 days to this timeline. For beneficiaries who need to complete step therapy from scratch, the total process from first provider visit to first Zepbound injection can stretch to 5 or 6 months.

Zepbound 15 mg produced 20.9% mean body-weight reduction over 72 weeks in SURMOUNT-1, with 63% of participants in that dose group losing at least 20% of their body weight 4.